BCR-ABL down-regulates the DNA repair protein DNA-PKcs

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Chronic myelogenous leukemia (CML) is characterized by the BCR-ABL fusion oncogene.
• DNA repair mechanisms are crucial for maintaining genomic stability.
• Dysregulation of DNA repair pathways contributes to cancer development and progression.

Purpose of the Study:

• To investigate the effect of BCR-ABL on the DNA repair protein DNA-PKcs in hematopoietic cells.
• To elucidate the mechanism of DNA-PKcs down-regulation by BCR-ABL.
• To explore the implications of DNA-PKcs down-regulation for CML pathogenesis and therapeutic strategies.

Main Methods:

• Stable and inducible BCR-ABL-expressing hematopoietic cell lines were utilized.
• BCR-ABL CD34(+) cells from CML patients were analyzed.
• Proteasome-dependent degradation assays were performed.
• Sensitivity to ionizing radiation was assessed.

Main Results:

• BCR-ABL expression leads to down-regulation of DNA-PKcs in hematopoietic cells, including CML patient cells.
• DNA-PKcs down-regulation is a proteasome-dependent process requiring tyrosine kinase activity.
• This down-regulation results in significant DNA repair deficiency and increased sensitivity to ionizing radiation.
• BCR-ABL also induces resistance to apoptosis, contributing to genetic instability in CML.
• Down-regulation of DNA-PKcs was reversible in CML cells.

Conclusions:

• BCR-ABL-mediated down-regulation of DNA-PKcs contributes to DNA repair deficiency and genomic instability in CML.
• The combined effects of DNA repair deficiency and apoptosis resistance provide a mechanism for CML blast crisis.
• Reversibility of DNA-PKcs down-regulation suggests a potential therapeutic strategy to delay CML progression.